{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

177 BQ Patents Affirmative Update

177 BQ Patents Affirmative Update - FILE NAME DDI 2008 ...

Info iconThis preview shows pages 1–5. Sign up to view the full content.

View Full Document Right Arrow Icon
FILE NAME DDI 2008 <BQ>    Your Name Patents Affirmative File Patents Affirmative File ................................................................................................................................. 1 Strategy Sheet ................................................................................................................................................. 2 Patents Key to Investors ................................................................................................................................ 3 Patents Key to Investors ................................................................................................................................ 4 Patents Key to Investors ................................................................................................................................ 5 Patents Key to Investors ................................................................................................................................ 6 Patents Key to Investors ................................................................................................................................ 7 Patents Key to Investors ................................................................................................................................ 8 Patents Key to Investors ................................................................................................................................ 9 Patents Key to Investors .............................................................................................................................. 10 Patents Key to Investors .............................................................................................................................. 11 Patents Key to Investors .............................................................................................................................. 12 Patents Key to Investors .............................................................................................................................. 13 Patents Key to Investors .............................................................................................................................. 14 Patents Key to Investors .............................................................................................................................. 15 Patents Key to Investors .............................................................................................................................. 16 Patents Key to Investors .............................................................................................................................. 17 Patents Key to R&D ..................................................................................................................................... 18 Patents Key to R&D ..................................................................................................................................... 19 Government Funding Bad ........................................................................................................................... 20 Patents Key to Innovation ........................................................................................................................... 21 Patents Key to Innovation ........................................................................................................................... 22 Strict System Bad ......................................................................................................................................... 23 Individualism ................................................................................................................................................ 24 1
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
FILE NAME DDI 2008 <BQ>    Your Name Strategy Sheet There’s really no literature about people rejecting federal or private investments just because they don’t  have a patents now. So you would have to argue that the KSR decision is so strict that it overwhelms any  incentive or investments given from the state governments.  The CP net benefits will probably be TSM bad and KSR Good. There are plenty of cards in the original  affirmative final that answers that. 2
Background image of page 2
FILE NAME DDI 2008 <BQ>    Your Name Patents Key to Investors Investors look at patents before getting involved Intellectual Asset Management, Fall 2003, http://www.iam-magazine.com/issues/Article.ashx? g=29c766f2-a9b8-4b94-89d5-d35b9ec8e614 But these are very much the exceptions. So far, nanotechnology is more about research and development , with most observers not expecting to see any substantial dollar returns for many years yet. According to Alan Marty, executive-in- residence with JP Morgan Partners in San Francisco, that makes intellectual property a key issue for investors when they are deciding whether to get involved with a particular nanotech company . “There are so many unknowns with nanotechnology and therefore so many risks. A patent portfolio is something that you can latch on to,” he says. 3
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
FILE NAME DDI 2008 <BQ>    Your Name Patents Key to Investors Investors focus on patents Jo Colton, Group Marketing Manager for Cambridge Network, 07/21/08, http://www.cambridgenetwork.co.uk/news/article/default.aspx?objid=49456 Where capital is available, the terms for funding may become simply uneconomic. 80 per cent of respondents believe key investors will either take a greater equity stake, or potentially look to secure their capital against the drug-makers' intellectual property (IP) assets. This reflects a trend gathering momentum within the industry where investors focus much more intently on the strength of valuable IP rights . Overall, 78 per cent agree that the climate for enabling biotechnology innovation has deteriorated within the last year, and 89 per cent believe some small and/or early stage companies will either fail or be bought out at unattractive levels.
Background image of page 4
Image of page 5
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}